19.65  -0.645 (-3.18%)		10-07 16:00
Open: 20.24 High: 20.52 Volume: 3,733,558		Pre. Close: 20.295 Low: 19.53 Market Cap: 6,275(M)

Short term
Mid term
Targets	6-month :	24.73	1-year :	28.88
Resists	First :	21.17	Second :	24.73
Pivot price	19.8
Supports	First :	18.32	Second :	16.55
MAs	MA(5) :	20.13	MA(20) :	19.14
	MA(100) :	17.04	MA(250) :	14.36
MACD	MACD :	0.6	Signal :	0.5
%K %D	K(14,3) :	71.3	D(3) :	77.4
RSI	RSI(14): 55.7
52-week	High :	21.17	Low :	9.56

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMRX ] has closed above bottom band by 43.7%. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	20.53 - 20.67	20.67 - 20.78
Low:	19.27 - 19.4	19.4 - 19.51
Close:	19.46 - 19.67	19.67 - 19.85

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Wed, 07 Oct 2026
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.2% Decline -- GF Value $8.20 vs Price $19.65 - GuruFocus

Wed, 07 Oct 2026
Amneal announces FDA approval and Amneal Pharmaceuticals stock matches its EUR 18.05 prior close - AD HOC NEWS

Tue, 06 Oct 2026
Amneal Pharmaceuticals stock heads into October 29 earnings - AD HOC NEWS

Sat, 03 Oct 2026
Amneal Pharmaceuticals, Inc. (AMRX) stock price, news, quote and history - Yahoo Finance Singapore

Mon, 28 Sep 2026
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- G - GuruFocus

Thu, 24 Sep 2026
Amneal Pharmaceuticals (NasdaqGS:AMRX) Stock Forecast & Analyst Predictions - Simply Wall Street

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	348 (M)
Shares Float	197 (M)
Held by Insiders	52 (%)
Held by Institutions	48.4 (%)
Shares Short	11,290 (K)
Shares Short P.Month	9,510 (K)

EPS	0.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.1
Profit Margin	5 %
Operating Margin	18.3 %
Return on Assets (ttm)	8.6 %
Return on Equity (ttm)	613 %
Qtrly Rev. Growth	9.8 %
Gross Profit (p.s.)	3.56
Sales Per Share	8.95
EBITDA (p.s.)	1.97
Qtrly Earnings Growth	157.1 %
Operating Cash Flow	201 (M)
Levered Free Cash Flow	-115 (M)

PE Ratio	40.93
PEG Ratio	1.8
Price to Book value	196.5
Price to Sales	2.19
Price to Cash Flow	34.08

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.